Locations:
SearchAdvertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Disease: Leukemia
Objective: The primary objective is to determine a possible maximum tolerated dose (MTD, defined in Section 7.1.1) for KB004 when administered up to 700 mg once weekly by IV infusion to subjects with hematologic malignancies.
Disease: Myelodysplastic Syndrome (MDS)
Objective: The primary objective is to Estimate Clinical Improvement rate including Complete Responses (CR), Marrow CR, Partial Responses (PR), Hematologic Improvement (HI) (CR+Marrow CR+PR+HI).
Disease: Myelodysplastic Syndrome (MDS)
Objective: The primary objective is to estimate the relative efficacy, as measured by CR at or before the Cycle 6 response assessment following randomization of pracinostat plus azacitidine versus placebo plus azacitidine.
Disease: Lung
Objective: The primary objective is to evaluate the efficacy of MPDL3280A in patients with PD-L1- positive locally advanced or metastatic NSCLC.
Photo by Russell Lee
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients
